References
- Stetler-Stevenson WG. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol 1996;148:1345–1350.
- DeClerck YA. Interactions between tumour cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer. Eur J Cancer 2000;36:1258–1268.
- Freireich EJ. Acute leukemia. A prototype of disseminated cancer. Cancer 1984;53:2026–2033.
- Hatfield KJ, Reikvam H, Bruserud Ø. The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia. Curr Med Chem 2010;17:4448–4461.
- Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161–174.
- Itoh Y, Takamura A, Ito N, et al. Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J 2001;20:4782–4793.
- Lin LI, Lin DT, Chang CJ, et al. Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia. Br J Haematol 2002;117:835–841.
- Chen S, Xue Y, Zhang X, et al. A new human acute monocytic leukemia cell line SHI-1 with t(6;11)(q27;q23), p53 gene alterations and high tumorigenicity in nude mice. Haematologica 2005;90:766–775.
- Li Z, Chen Z, Lu J, et al. Establishment of a nude mice model of human monocytic leukemia with CNS and multiorgan extramedullary infiltration. Eur J Haematol 2006;77:128–133.
- Wang C, Chen Z, Li Z, et al. The essential roles of matrix metalloproteinase-2, membrane type 1 metalloproteinase and tissue inhibitor of metalloproteinase-2 in the invasive capacity of acute monocytic leukemia SHI-1 cells. Leuk Res 2010;34:1083–1090.
- Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases regulators of the tumor microenvironment. Cell 2010;141:52–67.
- Li ZJ, Chen ZX, Cen JN, et al. The construction and expression of retroviral vector harboring tissue inhibitor of metalloprotease 2 gene. Suzhou Univ J Med Sci 2006 ;26:185–187.
- Valente P, Fassina G, Melchiori A, et al. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 1998;75:246–253.
- Kallakury BV, Karikehalli S, Haholu A, et al. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 2001;7:3113–3119.
- Butler GS, Butler MJ, Atkinson SJ, et al. The TIMP2 membrane type 1 metalloproteinase “receptor” regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem 1998;273:871–880.
- Lu KV, Jong KA, Rajasekaran AK, et al. Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line. Lab Invest 2004;84:8–20.
- Corcoran ML, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism. J Biol Chem 1995;270:13453–13459.
- Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 1993;157:351–358.
- Li ZJ, Chen ZX, Cen JN, et al. Overexpression of tissue inhibitor of metalloprotease-2 promotes proliferation and infiltration of human monocytic leukemia cells. Zhonghua Yi Xue Za Zhi 2006;86:2409–2412.